Product Description: Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities[1][2][3].
Applications: Cancer-programmed cell death
Formula: C14H14N4O3
References: [1]Hagner, P.R.et al.CC-122, a pleiotropic pathway modifier, mimics an IFN response and has antitumor activity in DLBCL.Blood.Aug 6;126(6):779-89./[2]Rasco DW, et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 Jan 1;25(1):90-98./[3]Nishi H, et al., Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2023 Oct;92(4):303-314.
CAS Number: 1015474-32-4
Molecular Weight: 286.291
Compound Purity: 99.37
Research Area: Cancer; Inflammation/Immunology
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: Apoptosis;E1/E2/E3 Enzyme;Molecular Glues;NF-κB
Deutsch
English
